Analystreport

Eagle Pharmaceuticals Inc (NASDAQ: EGRX) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $66.00 price target on the stock.

Eagle Pharmaceuticals, Inc.  (EGRX) 
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: investor.eagleus.com